Home › Leukemia › New Mexico › Albuquerque
Leukemia clinical trials in Albuquerque, NM
4 studies for Leukemia are looking for participants at sites in and around Albuquerque (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of New Mexico, Albuquerque
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
RecruitingObservational study
- University of New Mexico Cancer Center, Albuquerque
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- University of New Mexico Cancer Center, Albuquerque
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Albuquerque
About Leukemia
Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.
More about Leukemia on MedlinePlus
Leukemia trials in other cities
- Houston, TX31 studies
- Boston, MA27 studies
- New York City, NY21 studies
- Chicago, IL19 studies
- Los Angeles, CA17 studies
- Durham, NC14 studies
- Baldwin Park, CA14 studies
- Nashville, TN13 studies
- Columbus, OH13 studies
- Philadelphia, PA13 studies
- Atlanta, GA12 studies
- Milwaukee, WI12 studies
Other studies in Albuquerque
- Breast Cancer17 studies
- Non-Small Cell Lung Cancer17 studies
- Cancer (all types)14 studies
- Lung Cancer14 studies
- Ovarian Cancer13 studies
- Endometrial Cancer12 studies
- Cardiovascular Disease11 studies
- Metastatic Cancer11 studies
- Prostate Cancer10 studies
- Type 2 Diabetes10 studies
- Acute Myeloid Leukemia9 studies
- Melanoma9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.